Keyphrases
Chronic Lymphocytic Leukemia
100%
Israeli
19%
Rituximab
17%
Overall Survival
17%
Chronic Lymphocytic Leukemia Cells
16%
COVID-19
15%
Diffuse Large B-cell Lymphoma (DLBCL)
14%
Chimeric Antigen Receptor T Cells (CAR-T)
11%
Positron Emission Tomography-computed Tomography (PET-CT)
11%
Cyclophosphamide
11%
Israel
10%
European Research
10%
Leukemia Patients
9%
Working Diagnosis
9%
Elderly Patients
9%
Obinutuzumab
9%
BNT162b2
9%
Fludarabine
8%
Response Rate
8%
Progression-free Survival
8%
Richter Transformation
8%
Non-Hodgkin Lymphoma
8%
Hematological Malignancies
7%
COVID-19 Vaccine
7%
CD84
7%
Lymphoma Patients
7%
Relapsed or Refractory
7%
Prognostic Significance
7%
Lymphoma
7%
Chlorambucil
6%
BNT162b2 Vaccine
6%
Microenvironment
6%
B-cell Receptor Signaling
6%
Hodgkin
5%
Azacitidine
5%
Acalabrutinib
5%
Leukemia
5%
B Cell Receptor
5%
Clinical Trials
5%
Ibrutinib
5%
Bone Marrow
5%
Extranodal
5%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
72%
Diseases
24%
Overall Survival
17%
Rituximab
17%
Infection
10%
Cyclophosphamide
10%
Nonhodgkin Lymphoma
9%
Progression Free Survival
9%
Obinutuzumab
9%
Fludarabine
8%
B Lymphocyte Receptor
8%
Coronavirinae
7%
Messenger RNA
7%
Diffuse Large B Cell Lymphoma
7%
Chlorambucil
6%
Polyethylene Terephthalate
6%
Myelodysplastic Syndrome
6%
Clinical Trial
6%
SARS Coronavirus
6%
Chemotherapy
5%
COVID-19 Vaccine
5%
Azacitidine
5%
Acalabrutinib
5%
Hodgkin Disease
5%
Leukemia
5%
Ibrutinib
5%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
69%
Overall Survival
15%
Diseases
14%
Diffuse Large B-Cell Lymphoma
14%
COVID-19
13%
Leukemia Cell
11%
Rituximab
9%
Hematologic Malignancy
8%
Richter's Transformation
8%
Chimeric Antigen Receptor T-Cell
7%
Obinutuzumab
7%
Progression Free Survival
7%
Lymphocyte
7%
Retrospective Study
6%
B Lymphocyte Receptor
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Non-Hodgkin Lymphoma
6%
B Cell
5%
Chronic Lymphocytic Leukemia
5%
Messenger RNA
5%
Acalabrutinib
5%
Cancer
5%
Polyethylene Terephthalate
5%
Myelodysplastic Syndrome
5%
Positron Emission Tomography-Computed Tomography
5%
Infection
5%